MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

ACADIA Pharmaceuticals Inc

Fechado

SetorSaúde

21.38 0.75

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.01

Máximo

21.48

Indicadores-chave

By Trading Economics

Rendimento

7.7M

27M

Vendas

20M

265M

P/E

Médio do Setor

15.793

35.739

Margem de lucro

10.079

Funcionários

653

EBITDA

21M

40M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+40.11% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-426M

3.6B

Abertura anterior

20.63

Fecho anterior

21.38

Sentimento de Notícias

By Acuity

50%

50%

149 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

ACADIA Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de out. de 2025, 23:30 UTC

Ações em Alta

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 de out. de 2025, 21:21 UTC

Ganhos

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 de out. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 de out. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 de out. de 2025, 23:39 UTC

Conversa de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 de out. de 2025, 23:00 UTC

Conversa de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Scales's JV Buyout Lauded by Bull -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Forex and Fixed Income Roundup: Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de out. de 2025, 21:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 de out. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

2 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de out. de 2025, 20:49 UTC

Aquisições, Fusões, Aquisições de Empresas

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 de out. de 2025, 20:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 de out. de 2025, 19:20 UTC

Conversa de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 de out. de 2025, 19:10 UTC

Conversa de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 de out. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparação entre Pares

Variação de preço

ACADIA Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

40.11% parte superior

Previsão para 12 meses

Média 29.76 USD  40.11%

Máximo 40 USD

Mínimo 17 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para ACADIA Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

12

Comprar

5

Manter

1

Vender

Pontuação Técnica

By Trading Central

14.845 / N/ASuporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Neutral Evidence

Sentimento

By Acuity

149 / 371 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat